# Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Source: https://onco.cc/trials/nct07764978/  
OnCo record `nct07764978` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daratumumab, Dexamethasone, Isatuximab in multiple myeloma, run by AstraZeneca, now recruiting.

## Summary

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT is a phase 3 interventional study registered as NCT07764978 by AstraZeneca, with 750 participants planned, started 2026-06-26 and due to reach its primary completion in 2029-01-11. Interventions recorded: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide. Conditions listed: Newly Diagnosed Multiple Myeloma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07764978
- Phase: 3
- Setting: Phase III Open-Label, Randomised Study of Consolidation With AZD0120 (Dual-Targeting BCMA/CD19 CAR-T) vs Continuous Standard Therapy in NDMM Patients Ineligible for ASCT as Initial Therapy (DURGA-5)
- Sponsor: AstraZeneca
- Enrolled: 750

## Sources

- ClinicalTrials.gov NCT07764978: https://clinicaltrials.gov/study/NCT07764978

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [AZD0120](https://onco.cc/drugs/azd0120/), [Bortezomib](https://onco.cc/drugs/bortezomib/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Daratumumab](https://onco.cc/drugs/daratumumab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Isatuximab](https://onco.cc/drugs/isatuximab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct07764978.json